Figures & data
FIGURE 1. Urinary excretion of protein (a) and nitrite (b) in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). n = 5 in each experimental group. Values are mean ± SEM. *p < 0.05 versus control.
![FIGURE 1. Urinary excretion of protein (a) and nitrite (b) in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). n = 5 in each experimental group. Values are mean ± SEM. *p < 0.05 versus control.](/cms/asset/18536ff4-bc56-490b-87bf-2f7036fb00de/irnf_a_461683_f0001_b.gif)
FIGURE 2. Urinary excretion of Na+ (a), creatinine (b), and plasma creatinine (c) values in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.
![FIGURE 2. Urinary excretion of Na+ (a), creatinine (b), and plasma creatinine (c) values in control and ARF rats treated with or without candoxatril (30 mg/kg/day; orally, 3 weeks). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.](/cms/asset/8e0fe390-e5ee-45f0-b656-0c4450d241f8/irnf_a_461683_f0002_b.gif)
FIGURE 3. Vascular responses to (a) AngII (2.5, 5, 10, and 25 ng), (b) ET-1 (5, 10, and 25 ng), and (c) U46619 (10, 50, and 100 ng), a TxA2 mimetic, in isolated kidneys prepared from control (Control) or ARF rats with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) treatment. Numbers in the parentheses are the number of animals in each group. Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.
![FIGURE 3. Vascular responses to (a) AngII (2.5, 5, 10, and 25 ng), (b) ET-1 (5, 10, and 25 ng), and (c) U46619 (10, 50, and 100 ng), a TxA2 mimetic, in isolated kidneys prepared from control (Control) or ARF rats with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) treatment. Numbers in the parentheses are the number of animals in each group. Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.](/cms/asset/dab51641-7bc0-401b-be00-8c26036ebade/irnf_a_461683_f0003_b.gif)
FIGURE 4. Plasma level of AngII (a), ET-1 (b), and urinary excretion of TxB2 (c) in control (Control) and ARF rats treated with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) (n = 5 rats per group). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.
![FIGURE 4. Plasma level of AngII (a), ET-1 (b), and urinary excretion of TxB2 (c) in control (Control) and ARF rats treated with (ARF + Candox; Con + Candox) or without (ARF) candoxatril (30 mg/kg/day; orally, 3 weeks) (n = 5 rats per group). Values are mean ± SEM. *p < 0.05 versus control; **p < 0.05 versus ARF.](/cms/asset/6f843745-68ba-4344-98f8-8c522d2dfe2b/irnf_a_461683_f0004_b.gif)